Oncolytics Biotech (ONCY) Stock Price
Oncolytics Biotech Price
Oncolytics Biotech stock price
Oncolytics Biotech business model & stock analysis
Frequently asked questions about Oncolytics Biotech
8 analysts currently rate the Oncolytics Biotech stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Oncolytics Biotech to generate revenue of 834,465.10 USD and earnings per share of -0.30 USD.
Converted at the current exchange rate, the Oncolytics Biotech share trades at 0.47 EUR (0.53 USD).
The expected revenue of Oncolytics Biotech is 834,465.10 USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Oncolytics Biotech is -28.45 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Oncolytics Biotech is currently -1.78. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Oncolytics Biotech stock.
The price-to-sales ratio (P/S) of Oncolytics Biotech is currently 60.56. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Oncolytics Biotech stock.
The Eulerpool Quality Score for Oncolytics Biotech is 2/10.
The ISIN of Oncolytics Biotech is US68237V1035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Oncolytics Biotech is ONCY. The ticker symbol is used to trade Oncolytics Biotech shares on the stock exchange.
Oncolytics Biotech stock
Oncolytics Biotech Peer Group
All fundamentals and in-depth analysis of Oncolytics Biotech
Our stock analysis for Oncolytics Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncolytics Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.